Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training — latest FDA regulatory news.
Compass Pathways
NASDAQ: CMPS $15.19 USD
Compass Pathways is a public biotechnology company developing investigational psilocybin-based therapies and related care models for treatment-resistant depression and other mental-health conditions.
Company Info
Sector:Neuropsychiatry and Psychedelic Medicine
Headquarters:London, United Kingdom
Founded:2016
Website:compasspathways.com/
Clinical Development Pipeline
COMP360
Target: Psilocybin therapyRecent News
Compass’ psilocybin depression drug works for the long haul
BioSpace reports: Compass’ psilocybin depression drug works for the long haul.
Leadership Team
Kabir Nath
Chief Executive Officer